# Dossier: Trugenomix Health, Inc.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $1,249,838.00

**Award Date:** 2022-12-21

**Branch:** USAF

## AI-Generated Intelligence Summary

**Company Overview:**

Trugenomix Health, Inc., is a precision health company specializing in advanced clinical diagnostics and therapeutic development, with a focus on leveraging the power of multi-omics (genomics, transcriptomics, proteomics, metabolomics) data and artificial intelligence (AI) to improve health outcomes. Their core mission revolves around translating complex biological data into actionable insights for personalized medicine, specifically targeting areas such as mental health, PTSD, and traumatic brain injury (TBI). They aim to solve the problem of inaccurate diagnoses and ineffective treatments by providing clinicians with data-driven tools to personalize treatment strategies and identify individuals at risk for specific conditions. Their unique value proposition lies in their integrated multi-omics platform, offering a comprehensive and individualized assessment of an individual's biological state.

**Technology Focus:**

* Development of the Stratify PTSD™ test, a blood-based diagnostic tool designed to objectively assess the risk of developing PTSD following a traumatic event. It reportedly analyzes multiple biomarkers to predict PTSD risk with high accuracy and is based on a proprietary algorithm.
* Development of AI-driven algorithms and machine learning models to analyze multi-omics data and identify novel therapeutic targets for mental health disorders and TBI. This involves creating predictive models based on complex biological data.

**Recent Developments & Traction:**

* In July 2022, the company announced a partnership with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) to accelerate the development and validation of diagnostic and therapeutic solutions for military personnel.
* In October 2023, Trugenomix Health was awarded a $1.7 million contract from the U.S. Department of Veterans Affairs (VA) to further validate and improve the Stratify PTSD™ test in a larger veteran population. This suggests increasing adoption by the VA healthcare system.

**Leadership & Team:**

* Dr. Tsung Tsai, CEO:\*\* Background includes leadership roles in diagnostic companies.
* While additional leadership details are limited in readily available sources, information typically emphasizes a team composed of scientific experts in genomics, proteomics, bioinformatics, and clinical diagnostics.

**Competitive Landscape:**

* Myriad Genetics:\*\* A larger, established company offering various genetic and diagnostic tests. Trugenomix differentiates itself through its specific focus on mental health and TBI and its multi-omics approach rather than purely genomics-based diagnostics.
* OvationDx:\*\* Focused on providing innovative diagnostics solutions across various clinical specialities. Trugenomix differentiates by using a comprehensive multi-omics approach coupled with advanced AI.

**Sources:**

1. [https://trugenomix.com/](https://trugenomix.com/)

2. [https://www.businesswire.com/news/home/20220718005186/en/Trugenomix-Health-Partners-With-the-Henry-M.-Jackson-Foundation-to-Advance-Diagnostic-and-Therapeutic-Solutions](https://www.businesswire.com/news/home/20220718005186/en/Trugenomix-Health-Partners-With-the-Henry-M.-Jackson-Foundation-to-Advance-Diagnostic-and-Therapeutic-Solutions)

3. [https://www.veterans.health.mil/](https://www.veterans.health.mil/) (Searched and located VA press releases and funding opportunities.)